Figure 3.
Kaplan-Meier curves of patient fractions remaining without final normalization of platelet count (>150 × 109/L) after the start of caplacizumab treatment.
Kaplan-Meier curves of patient fractions remaining without final normalization of platelet count (>150 × 109/L) after the start of caplacizumab treatment.